Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)

Inclusion Criteria: * Newly diagnosed inflammatory breast cancer without distant metastases and have not received prior chemotherapy or immunotherapy. All breast cancer subtypes are allowed: Triple negative breast cancer (TNBC); Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative; HR-positive or HR-negative and HER2-positive Exclusion Criteria: * Clinical or radiologic evidence of distant metastases * Malignancy that progressed within the last five years. * Cardiac disease (history of and/or active disease) * HIV positive * Neuropathy ≥ Grade 2, per the NCI CTCAE v5.0 * Allogeneic stem cell or solid organ transplantation * Autoimmune disease where in the opinion of the Investigator would preclude the use of immunotherapy * Idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), or evidence of active pneumonitis * Tuberculosis * Pregnancy or lactation * Treatment with CD137 agonists or immune checkpoint-blockade therapies, including anti-CD40, anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies * Treatment with systemic immunosuppressive medications * Cardiopulmonary dysfunction * Clinically significant history of liver disease, including cirrhosis, autoimmune hepatic disorders, HIV infection, or active Hepatitis B or Hepatitis C * Subject is pregnant or nursing * Known hypersensitivity to the components of the study drugs(s)